FDA Ends REMS for Diabetes Drug Rosiglitazone

Drug Industry Daily
A A
The FDA is eliminating the risk evaluation and mitigation strategy for rosiglitazone-containing diabetes drugs, deciding enough is understood about its side effects.

To View This Article:

Login

Subscribe To Drug Industry Daily